{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:21:35Z","timestamp":1789410095508,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.cca.2017.07.002","type":"journal-article","created":{"date-parts":[[2017,7,4]],"date-time":"2017-07-04T03:30:14Z","timestamp":1499139014000},"page":"1-4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts"],"prefix":"10.1016","volume":"472","author":[{"given":"Yoshinao","family":"Muro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahisa","family":"Katsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2017.07.002_bb0005","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/01.bor.0000434664.37880.ac","article-title":"The diagnostic utility of autoantibodies in adult and juvenile myositis","volume":"25","author":"Tansley","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.cca.2017.07.002_bb0010","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/BOR.0000000000000116","article-title":"Inclusion body myositis: update","volume":"26","author":"Lahouti","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.cca.2017.07.002_bb0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s13317-016-0088-8","article-title":"Development and evaluation of a standardized ELISA for the determination of autoantibodies against cN-1A (Mup44, NT5C1A) in sporadic inclusion body myositis","volume":"7","author":"Kramp","year":"2016","journal-title":"Auto Immun. Highlights"},{"key":"10.1016\/j.cca.2017.07.002_bb0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/acr.22600","article-title":"Cytosolic 5\u2032-nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases","volume":"68","author":"Lloyd","year":"2016","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.cca.2017.07.002_bb0025","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","article-title":"Disease specificity of autoantibodies to cytosolic 5\u2032-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases","volume":"75","author":"Herbert","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cca.2017.07.002_bb0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13075-015-0573-x","article-title":"Anti-PM\/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma","volume":"17","author":"Muro","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cca.2017.07.002_bb0035","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nmd.2009.11.003","article-title":"Inclusion body myositis: MRC centre for neuromuscular diseases, IBM workshop, London, 13 June 2008","volume":"20","author":"Hilton-Jones","year":"2010","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.cca.2017.07.002_bb0040","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","article-title":"ENMC IBM working group, 188th ENMC international workshop: inclusion body myositis, 2\u20134 December 2011, Naarden, The Netherlands","volume":"23","author":"Rose","year":"2013","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.cca.2017.07.002_bb0045","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1002\/art.38866","article-title":"Autoantibodies to DNA mismatch repair enzymes in polymyositis\/dermatomyositis and other autoimmune diseases: a possible marker of favorable prognosis","volume":"66","author":"Muro","year":"2014","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cca.2017.07.002_bb0050","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","article-title":"Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis","volume":"49","author":"Hoshino","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cca.2017.07.002_bb0055","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2016-210282","article-title":"Cytosolic 5\u2032-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis","volume":"76","author":"Lilleker","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cca.2017.07.002_bb0060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/s10165-012-0812-9","article-title":"Validation of different sets of criteria for the diagnosis of Sj\u00f6gren's syndrome in Japanese patients","volume":"23","author":"Tsuboi","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.cca.2017.07.002_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215035","article-title":"Efficacy of immunosuppressive treatment in a systemic lupus erythematosus patient presenting with inclusion body myositis","author":"Varela-Rosario","year":"2016","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.cca.2017.07.002_bb0070","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3899\/jrheum.141206","article-title":"Inclusion body myositis in a patient with RNA polymerase III antibody-positive systemic sclerosis","volume":"42","author":"Vemulapalli","year":"2015","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.cca.2017.07.002_bb0075","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.clineuro.2011.03.016","article-title":"The association of sporadic inclusion body myositis and Sj\u00f6gren's syndrome in carriers of HLA-DR3 and the 8.1 MHC ancestral haplotype","volume":"113","author":"Rojana-udomsart","year":"2011","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.cca.2017.07.002_bb0080","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s10067-003-0715-4","article-title":"Inclusion body myositis in connective tissue disorders: case report and review of the literature","volume":"22","author":"Derk","year":"2003","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.cca.2017.07.002_bb0085","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/rheumatology\/41.4.440","article-title":"Primary Sj\u00f6gren's syndrome associated with inclusion body myositis","volume":"41","author":"Kanellopoulos","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cca.2017.07.002_bb0090","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0190-9622(08)81077-8","article-title":"In vivo complement C3 binding to the intercellular substance and cytoplasm of epidermal basal cells in a patient with scleroderma and inclusion body myositis","volume":"23","author":"Helm","year":"1990","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898117302528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898117302528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T12:29:14Z","timestamp":1535632154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898117302528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":18,"alternative-id":["S0009898117302528"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2017.07.002","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2017.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}